ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.73
0.23%
US Tech 100
21,170.80
-0.13%
S&P 500
6,037.59
1.06%
US Dollar vs CAD
1.44105
0.39%
Bitcoin
95,638.37
-3.69%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Eloxx Pharmaceuticals Inc (ELOX)

  7. Eloxx Pharmaceuticals Inc (ELOX) News

ELOX

Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ELOX
DateTimeSourceHeadlineSymbolCompany
08/20/20247:13PMEdgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ELOXEloxx Pharmaceuticals Inc
07/11/202410:46AMGlobeNewswire Inc.Eloxx Pharmaceuticals Provides Pipeline and Financing UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
04/16/20246:30AMGlobeNewswire Inc.Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
04/01/20243:02PMEdgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405NASDAQ:ELOXEloxx Pharmaceuticals Inc
03/29/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
03/21/20241:20PMEdgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
03/14/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
03/13/202410:42AMGlobeNewswire Inc.Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/26/20243:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/26/20243:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/26/20243:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/26/20243:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/24/20248:44PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELOXEloxx Pharmaceuticals Inc
01/24/20244:11PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/09/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
12/28/20233:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
11/13/20233:15PMGlobeNewswire Inc.Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
10/16/20234:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
10/09/20237:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/20/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/20/202312:26PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELOXEloxx Pharmaceuticals Inc
09/19/20237:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/18/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/18/20236:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/15/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/07/20239:14AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/07/20238:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013NASDAQ:ELOXEloxx Pharmaceuticals Inc
08/29/20233:32PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
08/21/20233:50PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
08/14/202310:56AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ELOX

Your Recent History

USOTC
PHIL
PHI (PK)
USOTC
ZHUD
Zhuding (PK)
USOTC
CRTG
Coretec (QB)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
TPTW
TPT Global Tech (CE)
USOTC
RDGL
Vivos (QB)
AMEX
KULR
KULR Technology
USOTC
HIRU
Hiru (PK)
NASDAQ
ILLR
Triller
USOTC
RDAR
Raadr (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
NYSE
IONQ
IonQ
USOTC
HLLK
Hallmark Venture (PK)
USOTC
SPZI
Spooz (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads